Virginia Cannabis Panel Weighs Retail Roadmap Against Safety, Access and Equity Concerns

Virginia’s bipartisan Joint Commission to Oversee Transition of the Commonwealth into a Retail Cannabis Market spent Monday afternoon plowing through several dense presentations that, taken together, underscored the stakes of moving from legalization on paper to a functioning, regulated marketplace in the real world.

Products in a display counter at the Cannabis Outlet in Portsmouth advertise high THC concentrations. (Photo by Ned Oliver/Virginia Mercury)

With retail sales still blocked after Gov. Glenn Youngkin’s 2025 vetoes, speakers pressed commissioners to leverage Virginia’s medical system, clamp down on illicit storefronts, and design rules that avoid corporate capture and keep wealth — and safety — inside the state.

The meeting at Richmond’s state Capitol built on earlier sessions in July and August as the commission readies recommendations for the 2026 session. Background from those hearings and the state’s maturing medical market framed Monday’s debate.

Virginia’s seed-to-sale tracking via Metrc is now live; patients report stronger oversight but still worry about access and affordability. Lawmakers have publicly weighed a 2026 start date if a retail bill can clear the governor’s desk.

Strong medical framework, but bad labeling and delivery gaps

JM Pedini, executive director of the Virginia chapter of the National Organization for the Reform of Marijuana Laws (NORML), told lawmakers that the commonwealth “is already regulating cannabis,” tracing a decade-long buildout from the 2015 launch of tightly controlled “pharmaceutical processors” to today’s vertically integrated medical operators with pharmacist consultations at the counter.

“Our program requires pharmacists … that is a serious added value that most medical cannabis programs in the nation do not have,” Pedini said, arguing Virginia’s consumer-safety regime — third-party testing, PMP reporting and recent adoption of Metrc — is among the nation’s strictest.

Pedini asked the commission to fix the code holes created when a bipartisan “boring, technical” operations bill was vetoed, leaving outdated percentage-based labeling rules for edibles and topicals and no clear legal definition for “delivery agents.”

“We will need to address this in 2026,” Pedini said, noting that patients need milligrams-per-dose front and center, as with Tylenol, not hard-to-parse percentages. Pedini added that medical dispensaries are secure, ID-gated spaces — “very nice, but also very boring” — and that clearer statewide language would help patients shopping online avoid allergens and dosing confusion.

The comments track with recent reporting that Virginia’s medical program is generating significant sales while tightening oversight through Metrc, even as patients flag affordability and access concerns — the very frictions that clean labeling and delivery rules could ease.

Clarity and patient safeguards remain crucial

Policy strategist Ngiste Abebe of the KND Group argued the key question is no longer if Virginia legalizes retail, but how — and warned that today’s half-legal landscape invites confusion and crime.

She urged the state to apply routine consumer-protection tools  such as truth-in-advertising and label accuracy, consider a state-issued decal to distinguish licensed shops and rethink local opt-outs that strand large populations far from legal stores while illicit delivery fills the void.

Citing California and New York, Abebe said broad local bans have made enforcement harder and squeezed licensees into a smaller map, driving up rents and limiting competition.

On patient access, Abebe pushed back on the idea that adult recreational use cannibalizes medical programs. During Massachusetts’ pandemic shutdown of recreational sales, medical registrations surged, she noted; many adult-use consumers still seek help for insomnia, pain and anxiety, making co-located medical/adult-use dispensaries valuable for both cost and counseling.

Abebe recommended protecting pediatric access, prohibiting separate “certification fees” in health care settings, and studying paths to insurance reimbursement — an affordability frontier other states have begun to test via workers’ compensation.

Her message dovetails with Virginia’s recent commission hearings, which emphasized learning from neighboring Maryland’s rapid 2023 rollout and New York’s slower equity-driven approach — two models commission members have studied since July.

Corporate dominance looms over market design

Cannabis operator-turned-analyst Max Jackson warned that giving medical incumbents an automatic head start is a policy choice with predictable outcomes: concentrated ownership, higher prices and a stubborn illicit market.

He contrasted “Path A,” a limited-license model seen in states like Illinois and Arizona, with a competitive phased rollout designed to seed many independent businesses from day one. In his telling, multistate operators openly tell investors they target oligopolistic environments — and Virginia’s vertically integrated medical structure already mirrors the “walled garden” some companies prefer.

Jackson pointed to bottlenecks and high prices where processing or retail licenses were scarce at launch, arguing that expensive legal cannabis simply can’t displace illicit sales.

“Arizona is perhaps the most direct example of regulatory capture,” Jackson said. “The incumbent’s own industry association was responsible for both bankrolling the campaign and drafting the language of the law itself. Then they launched sales in a record 79 days — a timeline that was logistically impossible for any new business to meet.”

Jackson advised lawmakers to separate medical incumbency from adult-use market power, curb vertical integration and time the rollout so new cultivators can get product to shelves.

Those warnings echo national reporting around Virginia’s stalled retail push. Supporters say equity and small business should be central, while opponents, including Youngkin, cite public health and safety risks and argue retail won’t kill the illegal market.

Lab tests expose risks in unregulated market

VCU forensic toxicologist and Cannabis Control Authority (CCA) board member Dr. Michelle Peace presented early results from “surveillance shopping” across Virginia’s health districts, building on a completed sweep in Washington, D.C.

Peace told the panel that her team has begun visiting “clubs,” vape shops and head shops marketing themselves as “dispensaries” — a term she said misleads consumers into assuming regulated, tested products.

In multiple visits, she reported lax ID checks, cash-only ATMs, staff giving “patently false” pharmacological advice, unlabeled vapes, and even a store requiring a customer to “take a hit” to try the product before leaving because returns weren’t allowed.

Back in the lab, untargeted and targeted analyses found products widely off-label, with many lacking any label at all.

Microbiological plates showed thriving mold and, in one “freebie” sample, coliform “indicative of fecal contamination.” A vape purchased as “Farm Bill compliant” tested at roughly 30% delta-8 THC and about 4% delta-9 THC; others contained purely synthetic cannabinoids with little known about toxicology.

Peace also described Virginia-code-defying THCA flower marketed as “legal,” and an adverse-event case where a pre-roll later tested with heavy microbial loads after a consumer suffered seizures at a concert.

Peace cautioned that until the state draws bright lines around licensing and labeling — and clarifies total-THC calculations already in code — consumers will be exposed to products that are mislabeled, adulterated or contaminated. That finding echoes commission testimony in August and broader coverage of Virginia’s muddled gray market amid continued retail delays.

What comes next

At its upcoming meeting in December, the commission is expected to translate these themes — consumer protection, medical-program integrity, competitive market architecture and illicit-market enforcement — into legislation text for the 2026 legislative session.

If lawmakers again send a retail framework to a newly elected governor, they’ll do so with fresh data, including the medical market’s performance under Metrc, fiscal estimates showing hundreds of millions in potential revenue over time and a growing record from other states on how design choices affect prices, equity and safety.

by Markus Schmidt, Virginia Mercury

Virginia Mercury is part of States Newsroom, a nonprofit news network supported by grants and a coalition of donors as a 501c(3) public charity. Virginia Mercury maintains editorial independence. Contact Editor Samantha Willis for questions: info@virginiamercury.com.